Marzullo C, Michotey O, Bourderont D, Levy J, Jung S, Tissot J, Huber-Braun C, Dorr R
Laboratoire de biochimie, centre hospitalier E-Muller, Mulhouse, France.
Ann Biol Clin (Paris). 1994;52(10):717-20.
We carried out a comparative study of various lipid parameters (apo AI and B, LpAI, Lp(a) and LpBCIII) in coronary heart disease patients (19 males and 4 females, mean age 61 +/- 11 years) and in controls (18 males and 14 females, mean age 55 +/- 3 years) selected so that cholesterol and triglycerides levels be beneath 6 and 2.3 mmol/l in both populations. Apo AI and B were analysed by immunonephelometry and lipoparticles by electroimmunodiffusion. Nonparametric statistics tests were performed on account of the small numbers in both groups. Our study confirms the protective effect of Lp AI but did not show an obvious superiority of Lp AI quantification compared to apo AI. It highlights the interest of Lp(a) as an independent and additional risk factor for atherogenesis: no obvious correlation with any other lipidic parameter was demonstrated. An increase in Lp(a) beyond 0.30 g/l increases atherogenic risk 2.5 fold. We did not show any benefit of LpBCIII quantification in 'normolipemic' coronary patients. In conclusion, a discriminant analysis including the apo B/apo AI and apo B/LpAI ratios and Lp(a) allows an accurate classification of 67% of the patients.
我们对冠心病患者（19名男性和4名女性，平均年龄61±11岁）和对照组（18名男性和14名女性，平均年龄55±3岁）的各种脂质参数（载脂蛋白AI和B、脂蛋白AI、脂蛋白(a)和脂蛋白BCIII）进行了比较研究，选取这两组人群时确保胆固醇和甘油三酯水平均低于6 mmol/l和2.3 mmol/l。载脂蛋白AI和B通过免疫比浊法分析，脂蛋白颗粒通过电免疫扩散法分析。由于两组样本量较小，进行了非参数统计检验。我们的研究证实了脂蛋白AI的保护作用，但与载脂蛋白AI相比，未显示出脂蛋白AI定量的明显优势。它突出了脂蛋白(a)作为动脉粥样硬化发生的独立和额外危险因素的重要性：未发现与任何其他脂质参数有明显相关性。脂蛋白(a)超过0.30 g/l会使动脉粥样硬化风险增加2.5倍。我们未显示脂蛋白BCIII定量对“血脂正常”的冠心病患者有任何益处。总之，包括载脂蛋白B/载脂蛋白AI和载脂蛋白B/脂蛋白AI比值以及脂蛋白(a)的判别分析能够准确分类67%的患者。
